Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo
作者:Peng Xu、Jiarui Chu、Yuqiao Li、Yaping Wang、Yong He、Chuanmin Qi、Jin Chang
DOI:10.1016/j.bmc.2019.06.001
日期:2019.10
4-Anilinoquinazoline derivatives function as tyrosine kinase inhibitors (TKIs). Novel TKIs are needed for cancer mutations and drug-resistant cells. We designed and synthesized 4-anilinoquinazoline derivatives with substitutions at quinazoline positions 6, 7 and 4 using a binding model with multi-target receptor tyrosine kinases, and assessed their antitumor activity against five human tumor cell lines (HepG2,
4-苯胺基喹唑啉衍生物起酪氨酸激酶抑制剂(TKIs)的作用。癌症突变和耐药细胞需要新型TKI。我们使用具有多目标受体酪氨酸激酶的结合模型设计并合成了在喹唑啉6、7和4位具有取代基的4-苯胺基喹唑啉衍生物,并评估了它们对五种人类肿瘤细胞系(HepG2,A549,MCF-7, DU145,SH-SY5Y)。大多数化合物抑制所有癌细胞类型的增殖,有些化合物表现出选择性抑制作用。对于A549细胞,化合物21、25、27和37的IC 50值分别为7.588、8.619、6.936和8.516μM,远低于吉非替尼(14.803μM)的IC 50值。化合物32的IC 50DU145细胞的2.756μM值。代表性化合物40对所有癌细胞类型均具有无与伦比的广谱抑制作用,并显示出对血管内皮生长因子受体2(VEGFR-2),血小板源性生长因子受体β(PDGFR-β)和表皮生长因子受体的抑制作用(EGFR)与IC